Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass: a controlled, randomized study. 1979

G A Pantely, and S H Goodnight, and S H Rahimtoola, and B J Harlan, and H DeMots, and L Calvin, and J Rösch

Fifty patients who underwent aortocoronary saphenous-vein bypass-graft surgery were randomly assigned to one of three groups to determine the effects of antiplatelet or anticoagulant therapy on graft patency. Twenty-four patients served as controls; 13 patients received aspirin (325 mg three times a day) and dipyridamole (75 mg three times a day); and 13 patients received closely regulated warfarin therapy. Medications were begun on the third post-operative day. Six months after surgery, all patients underwent coronary angiography to assess graft patency. There were no statistically significant differences between groups in various clinical, hemodynamic and angios, 27 of 33 grafts (82 per cent) with aspirin and dipyridamole and 29 of 37 grafts (78 per cent) with warfarin (P less than 0.5), all patients had at least one patent graft. Postoperative treatment either with aspirin and dipyridamole or with warfarin failed to improve the patency of the grafts.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004176 Dipyridamole A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Antistenocardin,Apo-Dipyridamole,Cerebrovase,Cléridium,Curantil,Curantyl,Dipyramidole,Kurantil,Miosen,Novo-Dipiradol,Persantin,Persantine,Apo Dipyridamole,Novo Dipiradol
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect

Related Publications

G A Pantely, and S H Goodnight, and S H Rahimtoola, and B J Harlan, and H DeMots, and L Calvin, and J Rösch
January 1990, The Journal of cardiovascular surgery,
G A Pantely, and S H Goodnight, and S H Rahimtoola, and B J Harlan, and H DeMots, and L Calvin, and J Rösch
April 1980, The New England journal of medicine,
G A Pantely, and S H Goodnight, and S H Rahimtoola, and B J Harlan, and H DeMots, and L Calvin, and J Rösch
April 1980, The New England journal of medicine,
G A Pantely, and S H Goodnight, and S H Rahimtoola, and B J Harlan, and H DeMots, and L Calvin, and J Rösch
April 1980, The New England journal of medicine,
G A Pantely, and S H Goodnight, and S H Rahimtoola, and B J Harlan, and H DeMots, and L Calvin, and J Rösch
April 1980, The New England journal of medicine,
G A Pantely, and S H Goodnight, and S H Rahimtoola, and B J Harlan, and H DeMots, and L Calvin, and J Rösch
October 1996, The New England journal of medicine,
G A Pantely, and S H Goodnight, and S H Rahimtoola, and B J Harlan, and H DeMots, and L Calvin, and J Rösch
October 1996, The New England journal of medicine,
G A Pantely, and S H Goodnight, and S H Rahimtoola, and B J Harlan, and H DeMots, and L Calvin, and J Rösch
September 2018, JAMA,
G A Pantely, and S H Goodnight, and S H Rahimtoola, and B J Harlan, and H DeMots, and L Calvin, and J Rösch
September 2018, JAMA,
G A Pantely, and S H Goodnight, and S H Rahimtoola, and B J Harlan, and H DeMots, and L Calvin, and J Rösch
December 2017, Platelets,
Copied contents to your clipboard!